drugset

drugset / Trial / NCT06046222

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222 ↗

Phase 2 Active not recruiting 45 enrolled NS Pharma, Inc. Nippon Shinyaku Co., Ltd. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.

Timeline

Start: 2023-12-20
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NS-229	Unknown	—	—

Indications